WEIGHT MANAGEMENT
Tirzepatide
A once-weekly dual incretin medication prescribed within a monitored plan for eligible adults with weight-management needs.
What it is
Tirzepatide is a prescription medication that activates GIP and GLP-1 receptors. It may be used for chronic weight management after a clinician evaluates medical history and eligibility.
How it works
The medication affects signaling involved in appetite, satiety, gastric emptying, and glucose regulation. Doses are usually advanced gradually to limit gastrointestinal side effects. The care team monitors response, nutrition, contraindications, and adverse effects.
Who it is for
- Adults who meet criteria for prescription weight management
- Patients needing a structured medication and lifestyle plan
- Patients able to follow titration instructions and scheduled review
Mechanism in depth
Tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors. GIP is a second incretin hormone that complements GLP-1 signaling. The dual mechanism appears to produce greater average weight loss than GLP-1-only drugs in head-to-head trials. Once-weekly injection with slow titration reduces side effects during ramp-up.
What outcomes to expect
Similar time course to semaglutide with typically larger average weight loss at equivalent duration. Improvements in blood sugar control, blood pressure, and lipid markers often follow the weight change. Individual response varies with adherence, dose tolerance, and lifestyle factors.
Individual response varies. GPLX does not guarantee results. Your physician sets expectations based on your health history and lab findings.
Common side effects
Similar to semaglutide: nausea, constipation, diarrhea, heartburn, and injection site reactions. Gastroparesis symptoms can appear or worsen. Muscle loss during rapid weight loss requires attention to protein intake and resistance training.
Monitoring schedule
Baseline labs, then follow-up at four weeks after the initial dose and after each dose increase. Ongoing monitoring occurs monthly during titration, then every three months.
Not appropriate if
Not appropriate if you have a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, active pancreatitis, severe gastroparesis, uncontrolled diabetic retinopathy without ophthalmology involvement, or if pregnancy is possible or planned in the near term.
Biomarkers reviewed with this treatment
Your physician reviews these markers before and during therapy. Click any marker for a plain-English explanation of what it measures and why it matters.
This treatment is only available after a physician consultation. Book your $149 intake to see if it is appropriate for you.
Book a $149 Consultation